Patients who had prior treatment with HMAs, or with ESAs followed by HMAs, showed modest clinical activity with imetelstat. Overall, while these analyses were limited by the small number of patients ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical ...

New analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS Additional poster ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...

This is a follow-up coverage of the Geron Corp., a small biotech company that markets first-in-class drug Imetelstat for the treatment of myelodysplastic syndrome (MDS). The first three full-quarter ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including ...

Please provide your email address to receive an email when new articles are posted on . Almost 40% of imetelstat-treated patients achieved a statistically significant benefit of red blood ...

On June 6, 2024, the US Food and Drug Administration (FDA) approved imetelstat (RYTELO, Geron) for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent ...